# AmerisourceBergen Corporation (ABC) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ABC/thesis · /stocks/ABC/memo

## Financial Snapshot

---
source: coverage-next-full
type: step_output
step: 04
ticker: ABC
company: Cencora, Inc.
sector: Health Care
generated: 2026-05-27
---

### Step 04 — Financial Snapshot & Quality: Cencora, Inc. (COR)

#### 1. Income Statement Analysis (5-Year)

##### Revenue & Profitability ($ millions, except per-share)

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|--------|--------|--------|--------|--------|--------|
| Revenue | $213,989 | $238,587 | $262,173 | $293,959 | $321,333 |
| YoY Growth | — | +11.5% | +9.9% | +12.1% | +9.3% |
| Gross Profit | ~$9,316 | $8,296 | $8,959 | $9,910 | $11,479 |
| Gross Margin | ~4.4% | 3.5% | 3.4% | 3.4% | 3.6% |
| Segment Operating Income | — | ~$2,925 | $3,289 | $3,648 | $4,223 |
| GAAP Operating Income | — | $1,908 | $2,341 | $2,175 | $2,629 |
| GAAP Net Income | ~$1,703 | ~$1,700 | ~$1,716 | ~$1,503 | ~$1,517 |
| Adj. EPS (Diluted) | ~$10.00 | ~$10.50 | ~$12.00 | ~$13.50 | ~$15.50 [est.] |
| GAAP EPS (Diluted) | ~$8.18 | ~$8.35 | ~$8.74 | ~$7.76 | ~$8.50 [est.] |

Note: FY2024 GAAP EPS suppressed by $418M goodwill impairment; FY2025 by $724M impairment.
FY2025 adjusted EPS guidance: $17.65-$17.90 per company guidance (FY2026 raising implies FY2025 actual was in that range pre-raise).

##### Statement Quality Adjustments

**1. LIFO Inventory Accounting:**
Cencora uses LIFO (last-in, first-out) for its U.S. pharmaceutical inventory. When drug prices inflate, LIFO creates an expense (LIFO expense) that reduces reported gross profit. When prices deflate (as in FY2024-FY2025 due to generic deflation and brand price decreases), LIFO creates a credit:
- FY2023: LIFO expense ($204.6M) — reduced gross profit
- FY2024: LIFO credit $52.2M — added to gross profit
- FY2025: LIFO credit $76.9M — added to gross profit

**Adjustment:** To compare periods, add back LIFO expense or subtract LIFO credit.

**2. Antitrust Litigation Settlement Gains:**
Recurring gains from pharmaceutical manufacturer antitrust settlements (recorded as COGS reduction):
- FY2023: $239.1M
- FY2024: $170.9M
- FY2025: $236.4M

**Adjustment:** These are recurring but irregular; should be treated as below-the-line items.

**3. Goodwill Impairments (PharmaLex):**
- FY2024: $418M goodwill impairment (PharmaLex)
- FY2025: $724M goodwill impairment (PharmaLex + equity investment impairment $113.5M)

**Adjustment:** Remove from operating income; these reflect acquisition overpayment, not operating performance.

**4. Opioid Litigation:**
- FY2023: $24.7M credit (received H.D. Smith escrow)
- FY2024: $227.1M expense
- FY2025: $60.7M credit

**Adjustment:** Non-recurring in nature; exclude from adjusted earnings.

**5. Turkey Hyperinflation:**
- FY2023: ($87.0M) expense
- FY2024: ($54.1M) expense
- FY2025: ($49.6M) expense

Ongoing due to Turkish Lira devaluation; reflects the risk of Alliance Healthcare's Turkey operations.

**6. Acquisition-Related Charges:**
- FY2025: $291M deal & integration + $229M restructuring
- These are large and recurring as Cencora integrates Alliance Healthcare, PharmaLex, RCA, and OneOncology

**Net Effect of Adjustments on Operating Income:**
When removing impairments, litigation, and other non-recurring items, "adjusted" segment operating income of $4.22B in FY2025 (vs. $2.63B GAAP) better represents underlying earning power.

#### 2. Balance Sheet Analysis

##### Simplified Balance Sheet (September 30 estimates)

| Item | FY2022 est. | FY2023 est. | FY2024 est. | FY2025 est. |
|------|-------------|-------------|-------------|-------------|
| Cash & Equivalents | ~$2,200M | ~$2,600M | ~$3,100M | ~$4,000M |
| Accounts Receivable | ~$17,000M | ~$19,500M | ~$22,300M | ~$24,000M |
| Inventories | ~$17,000M | ~$19,000M | ~$20,500M | ~$22,000M |
| Total Current Assets | ~$40,000M | ~$44,000M | ~$48,000M | ~$53,000M |
| Goodwill + Intangibles | ~$14,000M | ~$16,000M | ~$15,000M | ~$20,000M [post-RCA] |
| Total Assets | ~$50,000M | ~$56,000M | ~$60,000M | ~$80,000M [post-RCA+OneOnc] |
| Accounts Payable | ~$36,000M | ~$42,000M | ~$47,000M | ~$51,000M |
| Long-Term Debt | ~$5,500M | ~$6,500M | ~$7,000M | ~$14,000M [post-RCA debt] |
| Stockholders' Equity | ~$2,800M | ~$3,100M | ~$3,200M | ~$3,000M |

Note: Balance sheet estimates are based on XBRL data plus filing text. Significant debt increase in FY2025 due to $1.8B senior notes + $1.5B term loan for RCA; further increase Q2 FY2026 for OneOncology ($4.6B+ new financing).

**Key observation:** Cencora runs with near-negative equity when goodwill is stripped out (net tangible equity is negative). This is a feature of capital-light, high-velocity distribution businesses with massive trade payable leverage — NOT a sign of insolvency. The company's true capital position is reflected in its free cash flow generation.

#### 3. Cash Flow Quality

| Metric | FY2023 | FY2024 | FY2025 |
|--------|--------|--------|--------|
| Operating Cash Flow | $3,900M | $3,500M | $3,900M |
| Capital Expenditures | $458M | $487M | $668M |
| Free Cash Flow | $3,442M | $3,013M | $3,232M |
| FCF / Net Income | ~2.0x | ~2.0x | ~2.1x |
| FCF / Adjusted Operating Income | ~79% | ~83% | ~77% |
| Capex / Revenue | 0.17% | 0.17% | 0.21% |

**Cash flow quality assessment: HIGH**
- OCF consistently exceeds reported net income (2x+ coverage) due to non-cash charges (D&A, impairments) and working capital mechanics
- Very capital-light in the distribution business (CapEx is 0.2% of revenue — nearly negligible)
- FY2025 FCF of $3.2B funds dividends ($437M), buybacks ($436M), and still contributes to debt reduction/M&A funding
- Guidance for FY2026 CapEx = $900M (significant increase for network expansion + OneOncology integration)

#### 4. Adversarial Research Sweep

##### 4a. Opioid Litigation

**Summary:** Cencora was a central participant in the U.S. opioid epidemic litigation. As a major distributor of opioid medications, the company is alleged to have prioritized profit over flagging suspicious orders.

**Settlement details:**
- National settlement (joint with MCK and CAH): ~$21B over 18 years; Cencora's share approximately $6.1B over 18 years
- FY2025: Still 13 more years of opioid payments remaining
- Annual opioid payment run rate: ~$400-500M
- Director settlement: $111M separate settlement with shareholders alleging board oversight failure
- FY2025 litigation line: $60.7M net credit (timing of payments/settlements)

**Risk assessment:** Material but contained. The settlement is structured; Cencora's cash flows ($3.2B FCF) comfortably cover annual payments. The primary risk is additional litigation from remaining plaintiffs not covered by the national settlement.

##### 4b. PharmaLex Acquisition Quality

**Issue:** Cencora acquired PharmaLex (regulatory consulting) in January 2023 for $1.4B. Within 18 months, it recorded $418M goodwill impairment (FY2024) and $724M impairment (FY2025) — together exceeding the acquisition price.

**Analysis:** This represents a clear acquisition failure. Management overpaid significantly for PharmaLex. The company is now exploring strategic alternatives for the consulting services businesses. This raises questions about M&A discipline, though it is worth noting that Alliance Healthcare (much larger acquisition) has performed well.

##### 4c. Cybersecurity Incident (March 2024)

**Issue:** In March 2024, Cencora experienced a cybersecurity event where data was exfiltrated from its information systems. The incident was disclosed in the FY2024 10-K.

**Impact:** Costs recorded in "Other, net" within restructuring; amount not separately quantified but described as "majority of Other, net costs in FY2024." Likely a few tens of millions of dollars in remediation.

**Risk:** Ongoing. Cencora handles sensitive patient and pharmaceutical data; the 2024 breach increases the scrutiny of its cybersecurity posture. A follow-on incident could be more costly.

##### 4d. WBA Customer Concentration Risk

**Issue:** Walgreens Boots Alliance (WBA) is Cencora's largest customer. WBA has been facing serious financial difficulties — pharmacy reimbursement rate pressure, retail store losses, and ongoing restructuring. WBA has been closing stores and may reduce purchasing volumes.

**Impact:** WBA represents ~37% of Cencora's top-2 accounts receivable. Any significant reduction in WBA purchases would be material to Cencora's revenue.

**Mitigating factors:** Long-term supply agreement through 2029; Cencora cannot easily be replaced as WBA's distributor; WBA has contracted to purchase minimums.

##### 4e. OneOncology Acquisition Risk (Feb 2026)

**Issue:** Cencora acquired the remaining ~92% of OneOncology in February 2026 for ~$4.6B cash + $752M contingent consideration + assumed equity. Total fair value ~$7.4B. This is on top of RCA ($3.9B, Jan 2025). Combined, these two deals added ~$8B+ of cash outflow in 13 months, funded largely by new debt.

**Analysis:** The speed and scale of M&A is aggressive. PharmaLex failure is precedent for risk. However, OneOncology's community oncology model has a clearer strategic rationale — it directly drives specialty pharmaceutical volume at independent oncology practices that are Cencora's natural distribution customers. The key risk is integration execution and debt service burden.

#### 5. Financial Quality Summary

| Dimension | Assessment | Score (1-5) |
|-----------|-----------|-------------|
| Revenue quality | Highly visible; contract-based; diversified customer base | 4 |
| Earnings quality | Non-GAAP >> GAAP due to impairments; cash earnings are real | 3-4 |
| Cash flow quality | FCF consistently >2x net income; minimal CapEx | 5 |
| Balance sheet | Negative tangible equity; high goodwill; but manageable | 3 |
| Governance quality | Opioid oversight failures; PharmaLex error; but improving | 3 |
| M&A track record | Alliance Healthcare (success); PharmaLex (failure); RCA/OneOncology (TBD) | 3 |

**Overall Financial Quality: MODERATE-HIGH (3.5/5)**

Cash flow generation is excellent; the balance sheet is structurally leveraged (by design for a distribution company); GAAP earnings are heavily distorted by recurring non-cash items. Investors must focus on adjusted earnings and FCF.

#### Source Index

| ID | Source |
|----|--------|
| S1 | Cencora FY2025 10-K, EDGAR |
| S2 | Cencora FY2024 10-K, EDGAR |
| S3 | SEC XBRL, EDGAR |
| S4 | Tavily search — opioid settlement, cybersecurity |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ABC/fundamental

## Navigation

- Overview: /stocks/ABC
- Financials (this page): /stocks/ABC/financials
- Thesis: /stocks/ABC/thesis
- Investment Memo: /stocks/ABC/memo
- Coverage universe: /stocks